INTRODUCTION {#s1}
============

Approximately 1 million patients are annually diagnosed with gastric cancer (GC), and nearly 740,000 die of this disease ([@MCS004945SORC24]). Despite recent advances in GC treatment, long-term survival remains poor. Standard first-line therapy for unresectable, advanced, or metastatic gastric adenocarcinoma usually includes fluoropyrimidines and platinum compounds ([@MCS004945SORC2]), whereas more options are available at recurrence: ramucirumab ([@MCS004945SORC25]), paclitaxel ([@MCS004945SORC1]), their combination ([@MCS004945SORC58]), docetaxel ([@MCS004945SORC3]), and irinotecan ([@MCS004945SORC52]). Moreover, anti-PD1 immunotherapeutics can be considered an emerging treatment modality for metastatic GC ([@MCS004945SORC12]). In addition, molecular testing is required to define HER2 status of individual GC cases that guides prescription of trastuzumab ([@MCS004945SORC4]). However, selection of other drugs including ramucirumab is not based on any molecular diagnostic features.

Ramucirumab is a monoclonal therapeutic antibody that inhibits VEGF-mediated tumor angiogenesis by binding with VEGFR2 ([@MCS004945SORC31]). For the recurrent/advanced/metastatic GC it may be used either as monotherapy ([@MCS004945SORC47]; [@MCS004945SORC59]) or in combinations with other drugs (e.g., paclitaxel) ([@MCS004945SORC58]) and therapeutic regimens like FOLFIRI (folinic acid + irinotecan + 5-fluorouracil) or FOLFOX (oxaliplatin + leucovorin + 5-fluorouracil) ([@MCS004945SORC61]) or cisplatin + capecitabine ([@MCS004945SORC26]). In published clinical trials, overall response rate following treatment with ramucirumab or its above combinations was ∼30%--80% of the patients ([@MCS004945SORC58]; [@MCS004945SORC61]; [@MCS004945SORC59]; [@MCS004945SORC26]). The overall response rate includes a proportion of the patients who showed complete or partial response to the treatment or disease stabilization. Moreover, for the outcomes of combinational therapies, the impact of ramucirumab itself was unclear, thus suggesting that personalization of drug prescription is needed to increase efficacy of treatment ([@MCS004945SORC59]).

Gene expression profiles can be considered attractive next-generation biomarkers for cancer molecular diagnostics ([@MCS004945SORC16]). Expressions of single genes ([@MCS004945SORC39]) and their statistical combinations ([@MCS004945SORC54]) or activation levels of the whole molecular pathways ([@MCS004945SORC14]) may be useful to predict individual tumor response to the therapies. In turn, RNA sequencing is currently accepted as the gold standard analytic approach for high-throughput screening of gene expression ([@MCS004945SORC46]). Comparison of tumor gene expression profiles with the normal tissues is crucial for understanding individual mechanisms of cancer development, progression, and response to the targeted therapies ([@MCS004945SORC17]; [@MCS004945SORC43]).

However, RNA sequencing data sets obtained using different equipment, reagents, and protocols may be poorly compatible with each other ([@MCS004945SORC13]; [@MCS004945SORC9]), and ideally the same experimental platform should be used to compare the results ([@MCS004945SORC9]). We recently published an annotated database of RNA sequencing profiles termed Oncobox Atlas of Normal Tissue Expression (ANTE) ([@MCS004945SORC49]) that represents 142 solid tissue samples from human healthy donors killed in road accidents and 17 blood samples from healthy volunteers. It has statistically significant reference groups for 20 human tissues/organs including the stomach.

In this study, we report clinically annotated RNA sequencing profiles for 15 advanced GC patients that are fully compatible with the ANTE collection of normal tissues because they were profiled using the same equipment, reagents, and protocols with the same analytic thresholds. Among the others, the molecular data are linked with the information on clinical response to ramucirumab or its combinations. We used bioinformatic platform Oncobox ([@MCS004945SORC48]; [@MCS004945SORC15]; [@MCS004945SORC41]) to model ramucirumab efficiency based on RNA sequencing data and compared the output results with the known tumor response information. The Oncobox algorithm builds a personalized rating of target drugs for individual cancer patients. It is based on a simultaneous analysis of gene expression and molecular pathway activation in the patient\'s tumor and was shown to be effective in a prospective cohort of advanced cancer cases ([@MCS004945SORC40], [@MCS004945SORC42]) and in an ongoing prospective clinical investigation ([@MCS004945SORC41]). We observed here a statistically significant coincidence of the predicted and real GC clinical outcomes (AUC ≥ 0.7). These results demonstrate that gene expression analyses may uncover molecular mechanisms underlying ramucirumab resistance and, more importantly, may be useful to personalize prescription of ramucirumab to recurrent GC patients.

RESULTS {#s2}
=======

In this study, we investigated links between experimental gene expression profiles established by RNA sequencing of GC biosamples and the patient\'s clinical responses to the therapy containing therapeutic monoclonal antibody ramucirumab.

Clinical Data {#s2a}
-------------

In this study, we enrolled 15 patients with advanced or metastatic GC. The patients were receiving ramucirumab-containing therapies in two oncology hospitals: M.F. Vladimirsky Moscow Regional Research Clinical Institute and N.N. Blokhin National Medical Research Center of Oncology. In total, there were five female and 10 male patients enrolled with mean ages of 47.2 and 57.6 yr old, respectively ([Table 1](#MCS004945SORTB1){ref-type="table"}). All patients had progressive disease before receiving ramucirumab-containing therapy. Ramucirumab was prescribed as second-line therapy for both metastatic and primary tumors according to the National Comprehensive Cancer Network (NCCN) guidelines for stomach cancer (<https://www.nccn.org/patients/guidelines/content/PDF/stomach.pdf>). In 14 cases, primary GC specimens were analyzed, whereas in one case, a peritoneal metastasis of GC was investigated. The GC histological subtypes were tubular adenocarcinoma (*n* = 8), poorly cohesive adenocarcinoma, signet-ring cell type (*n* = 5), poorly cohesive adenocarcinoma, not otherwise specified (NOS) (*n* = 1), and omental metastasis of mucinous gastric adenocarcinoma (*n* = 1) ([Table 2](#MCS004945SORTB2){ref-type="table"}; [Fig. 1](#MCS004945SORF1){ref-type="fig"}). PCA analysis indicated that normal stomach and brain tissues from the ANTE database ([@MCS004945SORC49]) formed tight clusters, which were not mixed with GC samples from this study ([Fig. 1](#MCS004945SORF1){ref-type="fig"}E). In addition, GC samples were closer to normal stomach than to normal brain, indicating compatibility of the data sets ([Fig. 1](#MCS004945SORF1){ref-type="fig"}E). We used normal brain tissues as an outgroup in order to test the hypothesis that cancer and normal data sets in this study are compatible. Compatibility of data sets implies that biological differences (that manifest themselves as variance in gene expression space) are higher than any of the between data set differences. A PCA plot ([Fig. 1](#MCS004945SORF1){ref-type="fig"}E) shows that biological differences between gastric and neural tissues are higher than any of differences between two data sets. All patients underwent ramucirumab therapy either as monotherapy (*n* = 7) or in combination with paclitaxel (*n* = 6) or FOLFIRI regimen (*n* = 2) ([Table 3](#MCS004945SORTB3){ref-type="table"}). The registered clinical outcomes of treatment were "partial response," "stable disease," and "progressive disease." In this study, the patients were classified as either responders---for "partial response" and "stable disease" outcomes---or nonresponders---for "progressive disease" outcomes ([Table 3](#MCS004945SORTB3){ref-type="table"}).

![Histological subtypes of gastric cancer (GC) samples and principal component analysis (PCA). (*A*) Tubular adenocarcinoma; (*B*) poorly cohesive adenocarcinoma, signet-ring cell type; (*C*) poorly cohesive adenocarcinoma, NOS; (*D*) omental metastasis of mucinous gastric adenocarcinoma; and (*E*) PCA of stomach cancer samples, normal stomach samples from the ANTE database, and normal brain samples (outgroup) from the ANTE database ([@MCS004945SORC49]).](MCS004945Sor_F1){#MCS004945SORF1}

###### 

Patients' demographic and clinical information

  Patient ID   Sex      Age   Primary tumor/metastasis   TNM        Number of lines of therapy prior to ramucirumab
  ------------ -------- ----- -------------------------- ---------- -------------------------------------------------
  GC_4         Male     67    Primary                    T4aN3M0    1
  GC_5         Male     45    Primary                    T4N1M1     4
  GC_6         Male     65    Primary                    T4bNxM1    1
  GC_7         Male     79    Primary                    T3N0M0     2
  GC_8         Female   51    n/a                        T3NxM1     2
  GC_9         Male     59    Primary                    T4aN3bM0   2
  GC_11        Female   40    Primary                    TxNxM1     1
  GC_12        Male     41    Primary                    T3NxM0     1
  GC_13        Female   54    Primary                    T4aNxM1    1
  GC_14        Male     33    Primary                    T4N1M1     3
  GC_15        Female   31    Primary                    T4N2M1     1
  GC_16        Male     57    Primary                    T4N2M0     1
  GC_17        Female   60    Peritoneum metastasis      T4bN2M1    1
  GC_18        Male     63    Primary                    T4bN3M1    1
  GC_19        Male     67    Primary                    T4N1M1     1

###### 

Histological typing of gastric tumor samples investigated

  Patient ID   Histology
  ------------ -------------------------------------------------------
  GC_4         Poorly cohesive adenocarcinoma, signet-ring cell type
  GC_5         Tubular adenocarcinoma
  GC_6         Poorly differentiated tubular adenocarcinoma
  GC_7         Tubular adenocarcinoma
  GC_8         Poorly cohesive adenocarcinoma, signet-ring cell type
  GC_9         Poorly differentiated tubular adenocarcinoma
  GC_11        Poorly cohesive adenocarcinoma, signet-ring cell type
  GC_12        Poorly differentiated tubular adenocarcinoma
  GC_13        Poorly cohesive adenocarcinoma, signet-ring cell type
  GC_14        Tubular adenocarcinoma
  GC_15        Poorly cohesive adenocarcinoma, signet-ring cell type
  GC_16        Poorly cohesive adenocarcinoma NOS
  GC_17        Omental metastasis of mucinous gastric adenocarcinoma
  GC_18        Tubular adenocarcinoma
  GC_19        Poorly differentiated tubular adenocarcinoma

###### 

Ramucirumab treatment regimen for patients enrolled and their clinical outcome

  Patient ID   Treatment regimen                                                                                                                                                                         Clinical outcome      PFS (months)
  ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- --------------
  GC_4         Paclitaxel (80 mg/m^2^ days 1, 8, 15) + ramucirumab (8 mg/kg days 1, 15) − 28 d cycles, followed by 12 cycles of ramucirumab monotherapy (ramucirumab 8 mg/kg days 1, 15) − 28 d cycles   Stable disease        11
  GC_5         Ramucirumab monotherapy                                                                                                                                                                   Progressive disease   1
  GC_6         Seven courses: FOLFIRI (fluorouracil + leucovorin + irinotecan) + ramucirumab (8 mg/kg days 1, 15)                                                                                        Stable disease        5
  GC_7         Ramucirumab monotherapy                                                                                                                                                                   Progressive disease   5
  GC_8         Two courses paclitaxel + ramucirumab                                                                                                                                                      Progressive disease   2
  GC_9         Paclitaxel + ramucirumab                                                                                                                                                                  Progressive disease   9
  GC_11        Two courses: paclitaxel (80 mg/m^2^ days 1, 8, 15) + ramucirumab (8 mg/kg days 1, 15)                                                                                                     Progressive disease   3
  GC_12        Ramucirumab (8 mg/kg every 14 d)                                                                                                                                                          Progressive disease   6
  GC_13        Eight FOLFIRI + ramucirumab (8 mg/kg every 14 d)                                                                                                                                          Stable disease        8
  GC_14        Paclitaxel + ramucirumab                                                                                                                                                                  Progressive disease   1
  GC_15        11 injections: ramucirumab 8 mg/kg                                                                                                                                                        Partial response      8
  GC_16        15 injections: ramucirumab 8 mg/kg                                                                                                                                                        Stable disease        7
  GC_17        17 injections: ramucirumab 8 mg/kg + 4 injections paclitaxel                                                                                                                              Stable disease        11
  GC_18        14 injections: ramucirumab 8 mg/kg                                                                                                                                                        Stable disease        8
  GC_19        Six injections: ramucirumab 8 mg/kg                                                                                                                                                       Progressive disease   5

RNA Sequencing and Molecular Data Quality Control {#s2b}
-------------------------------------------------

The GC tissue specimens were the formalin-fixed paraffin-embedded (FFPE) tissue blocks stored in a clinical diagnostic laboratory for 4--49 mo before extraction of RNA. Previously we used the same experimental protocol for generating the Oncobox atlas of RNA sequencing profiles for normal human tissues from healthy donors ([@MCS004945SORC49]). We found that the profiles with the number of sequencing reads mapped on human genes exceeding 2.5 million were clustering tissue-specifically, whereas for the profiles with a lower number of mapped reads we observed biased clustering. A quality control (QC) threshold of 2.5 million gene-mapped reads was, therefore, established to identify high-quality RNA sequencing profiles ([@MCS004945SORC49]). In this study, we used the same Oncobox RNA sequencing and data processing protocol. All the current 15 GC RNA sequencing profiles passed the QC threshold and were further investigated. The original sequencing data were deposited to the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) with accession number PRJNA562149. Summary statistics of RNA sequencing (number of unmapped, uniquely mapped, and multimapped reads as well as average exon coverage) are depicted in [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004945/-/DC1).

Differentially Regulated Genes and Molecular Pathways {#s2c}
-----------------------------------------------------

According to differentially expressed gene analysis using DESeq2 software, only three genes passed the adjusted *P*-value threshold of 0.05 for "responders" on ramucirumab-containing therapies versus "nonresponders." These genes were *CHRM3* (cholinergic receptor muscarinic 3), *LRFN1* (leucine rich repeat and fibronectin type III domain containing 1), and *TEX15* (testis expressed 15, meiosis and synapsis associated). Of them, *CHRM3* was up-regulated in the responders, whereas the other genes were down-regulated. We found no previous literature reports on the implication of these genes in GC. However, *CHRM3* is involved in up-regulation of MAPK signaling and invasion and migration of prostate and colorectal cancer cells ([@MCS004945SORC5]; [@MCS004945SORC62]), and its genetic variants are associated with polycystic ovary syndrome ([@MCS004945SORC30]) and bladder cancer ([@MCS004945SORC57]) in Korean and Chinese populations. It is also known as the poor-prognosis biomarker in endometrial carcinoma ([@MCS004945SORC56]). In turn, mutations in the DNA repair gene *TEX15* are known to be linked with a high risk of prostate and breast cancers ([@MCS004945SORC33]).

We then calculated pathway activation levels of 3125 molecular pathways using the Oncobox software ([@MCS004945SORC48]) and tested them for differential activation between the responder and nonresponder tumors ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004945/-/DC1)). None of the pathways passed FDR threshold of 0.05, but the most significantly differential pathway according to the Wilcoxon rank sum test was the "Nectin adhesion pathway (positive regulation of JNK cascade)." This pathway is a fragment of the Nectin adhesion regulatory network, which is responsible for downstream positive regulation of JNK (c-Jun amino-terminal kinase) cascade. This pathway appeared to be less active in the treatment responders compared with the nonresponders, mostly as a result of decreased expression of *RAP1A*, *RAP1B*, and *SRC*, which are upstream regulators of the *CDC42* gene product ([Fig. 2](#MCS004945SORF2){ref-type="fig"}). Interestingly, activation of JNK signaling in GC cells can lead to enhanced resistance against platinum-based chemotherapeutics ([@MCS004945SORC60]) and microtubule-targeting drugs including paclitaxel ([@MCS004945SORC21]).

![The nectin adhesion pathway (positive regulation of JNK cascade) was more active in the nonresponder tumors (*upper* panel) than in the responder tumors (*lower* panel). The pathway is shown as an interacting network in which green arrows indicate activation. Gene expression values were geometrically averaged for responders and nonresponders. The depth of color of each node of the network corresponds to the logarithms of the case-to-normal (CNR) expression rate for each node, in which "normal" is a geometric average between normal tissue samples. The normal tissue gene expression profiles for healthy donors were taken from the ANTE database ([@MCS004945SORC49]). The scale represents the extent of up/down-regulation of the pathway nodes. PAL (pathway activation level) was calculated using the Oncobox software (described in Methods).](MCS004945Sor_F2){#MCS004945SORF2}

To assess the variance of the pathway activation level (PAL) and gene expression in the Nectin adhesion pathway (positive regulation of JNK cascade) between the cohorts of responders and nonresponders, we performed a nonpaired *t*-test and Wilcoxon test. We obtained for the *t*-test *P* = 0.01, for the Wilcoxon test *P* = 0.0003, and an absolute difference of average PAL scores of 0.35, thus indicating that the observed difference is significant considering variances of PAL in each cohort. Similarly, we performed DESeq2 differential gene expression analysis for all genes forming this pathway ([Table 4](#MCS004945SORTB4){ref-type="table"}). For all individual genes, the expression differences did not reach a *P* \< 0.05 significance threshold, thus confirming previous findings on superior robustness of molecular pathways as cancer biomarkers ([@MCS004945SORC7], [@MCS004945SORC8]; [@MCS004945SORC38]; [@MCS004945SORC14]).

###### 

DESeq2 differential analysis results for the five genes of the "Nectin adhesion pathway (positive regulation of JNK cascade)" pathway

  Gene      Log~2~ (fold change)   *P*-value
  --------- ---------------------- -----------
  *RAP1A*   −0.81                  0.12
  *CDC42*   −0.67                  0.17
  *RAP1B*   −0.34                  0.21
  *SRC*     −0.35                  0.22
  *FARP2*   −0.05                  0.84

To our knowledge, none of those three differential genes (*TEX15*, *CHRM3*, *LRFN1*)/molecular pathways identified was previously connected with the sensitivity to ramucirumab in cancer cells.

We then used the Oncobox platform to build a personalized rating of targeted therapeutics for each individual GC sample according to their simulated abilities to inhibit aberrantly regulated molecular pathways and drug target genes. To this end, the RNA sequencing profiles obtained for the GC samples were individually compared with the set of profiles for normal stomach tissues obtained from the ANTE database ([@MCS004945SORC49]). The output modeled drug efficiency values, termed balanced efficiency scores (BESs), which were obtained for 159 targeted therapeutics and prioritized drugs according to this score. A higher BES suggests higher predicted efficacy of a drug for an individual tumor ([@MCS004945SORC42]). We compared Oncobox BES values with the actual clinical outcomes of 15 ramucirumab-treated patients ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004945/-/DC1)) and found that BES values could predict the GC treatment response on ramucirumab-containing therapies with the quality metric area under the receiver operating characteristic (ROC) curve (ROC AUC) of 0.7 ([Fig. 3](#MCS004945SORF3){ref-type="fig"}A).

![The receiver operating characteristic (ROC) area under the curve (AUC) and histograms for predicting response to ramucirumab in gastric cancer (GC) patients using Oncobox balanced efficiency score (BES) values. (*A*) ROC AUC for the complete set of patients (*n* = 15). (*B*) ROC AUC for the patients who received ramucirumab monotherapy (*n* = 7). (*C*) Histogram and threshold value for the complete set of patients (*n* = 15). (*D*) Histogram and threshold value for the patients who received ramucirumab monotherapy (*n* = 7). The Oncobox BES of ramucirumab was used as a predictor of response. Patients were divided into two classes: "nonresponders," for progressive disease, and "responders," for stable disease and partial response (RECIST). Threshold values were assigned based on an assumption of the equality of type I and type II error rates.](MCS004945Sor_F3){#MCS004945SORF3}

The AUC value is the universal characteristic of biomarker robustness depending on its sensitivity and specificity ([@MCS004945SORC28]). This statistical approach is broadly applicable to different types of biomarkers in oncology ([@MCS004945SORC7]; [@MCS004945SORC32]; [@MCS004945SORC34]; [@MCS004945SORC51]; [@MCS004945SORC64]; [@MCS004945SORC18]). It positively correlates with the quality of a biomarker and varies from 0.5 to 1. The standard discrimination threshold is 0.7, and the parameters with greater AUC are considered good-quality biomarkers, and vice versa ([@MCS004945SORC11]).

The AUC value of 0.7 obtained for the whole set of patients ([Fig. 3](#MCS004945SORF3){ref-type="fig"}A) therefore suggests that the Oncobox BES value may serve as the good-quality predictive biomarker of GC clinical response for patients on ramucirumab. Importantly, reducing the patient cohort to those who received only ramucirumab monotherapy (seven cases) significantly improved performance of the BES-based predictions by increasing AUC to 0.75 ([Fig. 3](#MCS004945SORF3){ref-type="fig"}B). This can be explained by interference of other drugs (FOLFIRI, paclitaxel) in the non-monotherapy regimens.

To further study statistical performance of BES values, we pick up threshold values for cohorts of all patients (15 cases) and of those who received only ramucirumab monotherapy (seven cases). These thresholds were introduced to separate patients with different response status assuming equal importance for type I and type II errors ([Fig. 3](#MCS004945SORF3){ref-type="fig"}C,D); confusion matrices are shown in [Tables 5](#MCS004945SORTB5){ref-type="table"} and [6](#MCS004945SORTB6){ref-type="table"}. The sensitivity and specificity values observed were, respectively, 0.83 and 0.71 for all patients, and 1 and 0.75 for the monotherapy cohort.

###### 

Confusion matrix for a cohort of all patients (15 cases) using the threshold BES = 0.1, with sensitivity of 0.62 and specificity of 0.14

                  Cases predicted as responders   Cases predicted as nonresponders
  --------------- ------------------------------- ----------------------------------
  Responders      5                               3
  Nonresponders   6                               1

###### 

Confusion matrix for a cohort of all patients (15 cases), with sensitivity of 0.83 and specificity of 0.71

                  Cases predicted as responders   Cases predicted as nonresponders
  --------------- ------------------------------- ----------------------------------
  Responders      6                               1
  Nonresponders   2                               5

In an ongoing prospective trial of the Oncobox platform as a second-opinion tool for prescription of targeted therapeutics (NCT03724097), a BES threshold of 0.1 was arbitrarily set to discriminate between potentially effective and ineffective drugs. In this study, we tested this threshold for the original patient survival data. Eleven patients had greater and four patients had lower BES values ([Fig. 4](#MCS004945SORF4){ref-type="fig"}). Progression-free survival analysis revealed that Oncobox BES was able to predict better treatment outcomes for ramucirumab-containing therapies with hazard ratio 0.16 (95% CI, 0.034--0.74, *P* = 0.019; [Fig. 4](#MCS004945SORF4){ref-type="fig"}) and log-rank test *P* = 0.013. However, Cox proportional hazards analysis returned Cox *P* = 0.31. Such discrepant results between log-rank and Cox proportional hazards tests can be caused by small sample size. However, our further analysis showed that this BES threshold of 0.1 was suboptimal in terms of sensitivity and specificity values obtained, which were 0.62 and 0.14, respectively (confusion matrix shown on [Table 5](#MCS004945SORTB5){ref-type="table"}). Our results, therefore, suggest that using a greater BES threshold can be beneficial for algorithmic discrimination of the potential treatment responders and nonresponders, at least for the case of using ramucirumab in GC. Here we exemplify that a threshold of 3.1 results in much better values of sensitivity and specificity for our group of samples (0.83 and 0.71, respectively) ([Table 6](#MCS004945SORTB6){ref-type="table"}; [Fig. 3](#MCS004945SORF3){ref-type="fig"}C). Taken together, these data strongly suggest that the individual tumor responses for patients on ramucirumab can be predicted by using RNA sequencing profiles as the complex set of biomarkers.

![The Oncobox BES for ramucirumab predictive power for progression-free survival in GC patients receiving chemotherapy regimens with ramucirumab (*N* = 15). Cohorts of patients with BES values lower or higher than 0.1 are shown separately. The risk table is shown below the plot. Hazard ratio = 0.16 (95% CI, 0.034--0.74, *P* = 0.019). Log-rank test *P* = 0.013.](MCS004945Sor_F4){#MCS004945SORF4}

DISCUSSION {#s3}
==========

Ramucirumab is the therapeutic monoclonal anti-VEGFR2 antibody that is approved for advanced GC or gastroesophageal junction adenocarcinoma either as monotherapy or in combination with paclitaxel ([@MCS004945SORC25]; [@MCS004945SORC58]). It has been also approved for hepatocellular carcinoma ([@MCS004945SORC63]), non-small-cell lung cancer ([@MCS004945SORC27]), and colorectal cancer ([@MCS004945SORC50]). However, to our knowledge, so far there are no accepted biomarkers of ramucirumab efficiency in cancers ([@MCS004945SORC6]; [@MCS004945SORC55]). We were also unable to find in the public domain any clinically annotated high-throughput gene expression profiles linked with the patient responses on treatment with ramucirumab. Here we for the first time experimentally analyzed RNA sequencing profiles of GC tumors with the available clinical outcomes of ramucirumab-containing treatment regimens.

When comparing treatment responders versus nonresponders, we found three statistically significantly differentially expressed genes: *CHRM3*, *LRFN1,* and *TEX15*. The most significantly differential molecular pathway was the "Nectin adhesion pathway (positive regulation of JNK cascade)." It is a fragment of the Nectin adhesion regulatory network that is responsible for positive regulation of the JNK cascade. We found that this pathway was more active in the nonresponders ([Fig. 2](#MCS004945SORF2){ref-type="fig"}) as a result of stronger expression of the *RAP1A*, *RAP1B*, and *SRC* genes, which encode upstream regulators of the CDC42 protein. CDC42 is a member of the Rho GTPase family that is involved in regulation of cell migration in various types of human cancers ([@MCS004945SORC36]). In particular, *CDC42* inhibition significantly decreased proliferation, migration, and invasion of GC cells ([@MCS004945SORC23]). Therefore, down-regulation of CDC42 activators, such as RAP1A, RAP1B, and SRC, may potentially be linked with tumor response to ramucirumab, because ramucirumab is an anti-VEGFR2 antibody that inhibits various signaling pathways including the SRC pathway ([@MCS004945SORC19]). Thus, decreased activation of the Nectin adhesion pathway (positive regulation of JNK cascade) in tumors may be linked to a response to ramucirumab in GC tissues.

Targeting molecular pathways abnormally activated in individual tumors was previously proposed to be a promising strategy for personalized selection of targeted therapies ([@MCS004945SORC14]). Applicability of this approach to real-world cancer cases was tested in several clinical reports ([@MCS004945SORC40], [@MCS004945SORC42]). Here we present a retrospective cohort of advanced GC patients with known clinical outcomes for ramucirumab-containing therapies linked with high-throughput RNA sequencing profiles. Gene expression data were analyzed using the Oncobox bioinformatical platform for modeling the patient\'s tumor tissue sensitivity to ramucirumab. The predicted efficiencies were correlated with the actual tumor responses and progression-free survival data. Our results suggest that success of targeted therapies could be enhanced if guided by personalized analysis of gene expression. In this study, we experimentally profiled and bioinformatically investigated molecular data for 15 GC patients, with the smallest predicted response group including only four patients (ramucirumab BES \< 0.1). As far as we know, this is currently the largest group of publicly available high-throughput gene expression profiles associated with known response statuses of patients being treated with ramucirumab. However, larger patient cohorts will be required to validate the trends observed here and to develop transcriptomics-based companion diagnostics for ramucirumab to personalize its use in GC.

METHODS {#s4}
=======

Tissue Samples {#s4a}
--------------

All experimental biosamples were FFPE tumor tissue blocks. All biosamples were evaluated by a pathologist to confirm the tumor tissue origin, and only the specimens with tumor cell content of \>50% were further investigated. Of them, five GC samples were obtained from M.F. Vladimirsky Moscow Regional Research Clinical Institute and 10 GC samples were obtained from N.N. Blokhin National Medical Research Center of Oncology. The patients were 10 men and five women, whose mean ages were 57.6 and 47.2 yr old, respectively (with a range of 31--79 yr old).

The samples were clinically annotated and contained information about the patient\'s sex, age, diagnosis, and clinical history. For all the biosamples, informed written consent to participate in this study was collected from the patients or their legal representatives. The consent procedure and the design of the study were approved by the ethical committee of Vitamed Clinic, Moscow, protocol date 16.10.17. Clinical annotation of the tumor tissues investigated is summarized in [Tables 1](#MCS004945SORTB1){ref-type="table"}--[3](#MCS004945SORTB3){ref-type="table"}.

Preparation of Libraries and RNA Sequencing {#s4b}
-------------------------------------------

To isolate RNA, 10-µM-thick paraffin slices were trimmed from each FFPE tissue block using a microtome. RNA was extracted from FFPE slices using QIAGEN RNeasy FFPE Kit following the manufacturer\'s protocol. RNA 6000 Nano or Qubit RNA Assay kits were used to measure RNA concentration. The RNA integrity number (RIN) was measured using the Agilent 2100 Bio-Analyzer. For depletion of ribosomal RNA and library construction, the KAPA RNA Hyper with rRNA erase kit (HMR only) was used. Different adaptors were used for multiplexing samples in one sequencing run. Library concentrations and quality were measured using the Qubit ds DNA HS Assay kit (Life Technologies) and Agilent TapeStation. RNA sequencing was done at the Department of Pathology and Laboratory Medicine, University of California Los Angeles, using Illumina HiSeq 3000 equipment for single-end sequencing, 50-bp read length, for ∼30 million (mln) raw reads per sample. A data quality check was done on Illumina SAV. Demultiplexing was performed with the Illumina Bcl2fastq2 v 2.17 program. Sequencing data were deposited in the NCBI SRA under accession ID PRJNA562149. Summary statistics of RNA sequencing (number of unmapped, uniquely mapped, and multimapped reads as well as average exon coverage) is depicted in [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004945/-/DC1).

Processing of RNA Sequencing Data {#s4c}
---------------------------------

RNA sequencing FASTQ files were processed with STAR aligner ([@MCS004945SORC22]) in "GeneCounts" mode with the Ensembl human transcriptome annotation (Build version GRCh38 and transcript annotation GRCh38.89). Ensembl gene IDs were converted to HGNC gene symbols using the Complete HGNC data set (<https://www.genenames.org/>; database version from 2017 July 13). Expression levels were established for 36,596 annotated genes with the corresponding HGNC identifiers. The minimum number of uniquely mapped reads was 3.75 mln for studied biosamples, with the mean value of 9.78 mln. Differential gene expression analysis was performed using DESeq2 software ([@MCS004945SORC35]). PCA was performed for log-transformed DESeq2 normalized counts using the R prcomp function.

Molecular Pathway Analysis and Ranking of Target Drugs {#s4d}
------------------------------------------------------

Pathway activation levels were established using the Oncobox analytic software ([@MCS004945SORC48]) for 3125 molecular pathways extracted from the public databases Reactome ([@MCS004945SORC20]), NCI Pathway Interaction Database ([@MCS004945SORC45]), Kyoto Encyclopedia of Genes and Genomes ([@MCS004945SORC29]), HumanCyc ([@MCS004945SORC44]), Biocarta ([@MCS004945SORC37]), and QIAGEN pathway-central (available at <https://www.qiagen.com/us/shop/genes-and-pathways/pathway-central/>). The pathways investigated here are listed in [Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004945/-/DC1). The molecular pathways were visualized using the Oncobox pathway visualization/reconstruction tool ([@MCS004945SORC48]; [@MCS004945SORC15]).

The PAL scores were calculated according to the Oncobox method ([@MCS004945SORC10]). For the pathways interrogated, gene expression values were geometrically averaged for the treatment responder and separately for the nonresponder biosamples. These averaged gene expression data were normalized on the normal tissue expression profiles extracted from the ANTE database ([@MCS004945SORC49]). PAL scores were calculated as follows: $${PAL} = {\frac{\sum_{i = 1}^{n}\log_{10}\left( \frac{average\_ gene\_ expression\_ cancer}{average\_ gene\_ expression\_ norm} \right)}{n},}$$ in which PAL is pathway activation level, *n* is number of genes in a pathway, average_gene_expression_cancer is geometrically averaged gene expression value in all samples of a given cohort (treatment responders or nonresponders), and average_gene_expression_norm is geometrically averaged normalized gene expression value in control samples. Ranking of target cancer drugs using BES was performed as described previously ([@MCS004945SORC14]; [@MCS004945SORC42]; [@MCS004945SORC53]). The Oncobox software returned a personalized list of target drugs in descending order of predicted efficacy. The observed clinical responses were used for validation of the Oncobox predictions using ROC AUC analysis. ROC AUC was calculated using the R ROCR package. Patient survival analysis was performed using the R ggsurvplot package.
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